Breaking News

Gamma Biosciences Launches New Initiative Through Mirus Bio

Will develop novel, highly active lipid-polymer nanocomplexes for therapeutic mRNA delivery in vivo.

Author Image

By: Charlie Sternberg

Associate Editor

Gamma Biosciences, a global life sciences company serving the advanced therapy market, is launching an initiative through its subsidiary Mirus Bio to develop novel, highly active lipid-polymer nanocomplexes for therapeutic mRNA delivery in vivo.   The newly created initiative within Mirus Bio will develop improved mRNA delivery solutions leveraging Mirus’ proprietary formulations of membrane active polymers and lipids.   “mRNA vaccines and gene therapies require efficient deliver...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters